Ontology highlight
ABSTRACT:
SUBMITTER: Carmona FJ
PROVIDER: S-EPMC4747800 | biostudies-literature | 2016 Feb
REPOSITORIES: biostudies-literature
Carmona F Javier FJ Montemurro Filippo F Kannan Srinivasaraghavan S Rossi Valentina V Verma Chandra C Baselga José J Scaltriti Maurizio M
Pharmacology & therapeutics 20151202
The PI3K/AKT pathway is the focus of several targeted therapeutic agents for a variety of malignancies. In ERBB2-amplified breast cancer, the hyperactivation of this signaling cascade is associated with resistance to ERBB2-targeted therapy. This can occur through gain-of-function alterations or compensatory mechanisms that enter into play upon pharmacological pressure. The strong rationale in combining anti-ERBB2 agents with PI3K/AKT inhibitors, together with the identification of genomic altera ...[more]